Table 2.
Comparison of perioperative data between the training and validation sets
| Characteristic | Training set, n = 183 | Validation set, n = 147 | P-value |
| Age | 55 ( ± 7.1) | 55 ( ± 7.0) | 0.768 |
| Sex (male, %) | 80% | 83% | 0.570 |
| HBsAg positivity (%) | 82% | 80.3% | 0.777 |
| MELD | 14.7 (± 7.5) | 13.8 (± 7.0) | 0.284 |
| Waiting time from listing to transplantation (mo) | 1 (0-89) | 1 (0-81) | 0.051 |
| Size of tumor in explant (cm) | 3.0 (± 1.4) | 3.3 (± 2.1) | 0.116 |
| No. of tumor nodules in explant | 2.1 (± 1.8) | 2.3 (± 2.5) | 0.609 |
| Serum AFP level before time of LT (ng/mL) | 586 ( ± 3169) | 1719 ( ± 10541) | 0.169 |
| Salvage LT (%) | 19.1% | 24.5% | 0.281 |
| LDLT (%) | 112 (62.9%) | 91 (61.9%) | 0.908 |
| Microvascular invasion (%) | 28.8% | 32.2% | 0.713 |
| Well/mod differentiation | 87.5% | 81.1% | 0.237 |
| HCC recurrence | 24% | 23.8% | 1.000 |
| 5 yr disease-free survival (%) | 78.8% | 76.8% | 0.733 |
| 5 yr overall survival (%) | 80.8% | 78.7% | 0.733 |
HBsAg: Hepatitis B surface antigen; MELD: Model of end stage liver disease; AFP: Alpha fetoprotein; LT: Liver transplantation; LDLT: Living donor liver transplantation; Well/mod differentiation: Well or moderate differentiation; HCC: Hepatocellular carcinoma.